Expression and clinical significant of matrix metalloproteinase-2 in sebaceous carcinoma

Abstract

Abstract: AIM: To investigate the differential expression of MMP-2 between chalazion and sebaceous carcinoma tissues and explore the association of expression of MMP-2 with clinical pathological features and its clinical significance.METHODS: The expression of MMP-2 and VEGF in chalazion (20 cases) and sebaceous carcinoma tissues (50 cases) were detected using immunohistochemical method of SP.The microvessel density (MVD) was calculated by CD34 immunostaining in the tumor.The relationship between MMP-2 and clinicopathological characteristics, VEGF and MVD were analyzed.RESULTS: The positive expression rates of MMP-2(56%) in sebaceous carcinoma tissues were higher when compared with chalazion tissues(20%), the difference was statistically significant (P<0.05),but there was no difference in the expression of VEGF between sebaceous carcinoma and chalazion tissues.The expression of MMP-2 was positively correlated with recurrence and local infiltration in sebaceous carcinoma (P<0.05), while there was no significant association between expression of MMP-2 and clinical characteristics including age, histological grade, pathological type and duration of unrelated (P>0.05).Though MVD in MMP-2-positive tumors was higher than that in MMP-2-negative tumors (P<0.05), the expression of VEGF was not correlated with MMP-2 (r=-0.049,P=0.748).CONCLUSION: MMP-2 was over-expressed in sebaceous carcinoma tissues and may be involved in the progress of invasion and recurrence in sebaceous carcinoma via a VEFG-independent way to promote tumor angiogenesis.

Key words: metalloproteinase 2, microvessel density, sebaceous carcinoma, vascular endothelial growth factor

CLC Number:

R246.8

XU Xiao-fang, ZHANG Lei-lei, JIA Ren-bing, ZHOU Yi-xiong, SONG Xin, FAN Xian-qun. Expression and clinical significant of matrix metalloproteinase-2 in sebaceous carcinoma[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(5): 557-561.

References

[1] Kale SM, Patil SB, Khare N, et al. Clinicopathological analysis of eyelid malignancies--a review of 85 cases [J]. Indian J Plast Surg, 2012, 45(1):22-28.
[2] Xu XL, Li B, Sun XL, et al. Eyelid neoplasms in the Beijing Tongren eye centre between 1997 and 2006 [J]. Ophthalmic Surg Lasers Imaging, 2008, 39 (5):367-372.
[3] Mott JD, Werb Z. Regulation of matrix biology by matrix metalloproteinases [J]. Curr Opin Cell Biol, 2004, 16(5):558-564.
[4] Luo J, Zha S, Gage WR, et al. Alpha--methylacyl-CoA Racemase: a new molecular marker for prostate cancer [J]. Cancer Res, 2002, 62(8):2220-2226.
[5] Mumane MJ, Cai J, Shuja S, et al. Active MMP-2 effectively identifies the presence of colorectal cancer [J]. Int J Cancer, 2009, 125(12):2893-2902.
[6] Langers AM, Verspaget HW, Hawinkels LJ, et al. MMP-2 and MMP-9 in normal mucosa are independently associated with outcome of colorectal cancer patients [J]. Br J Cancer, 2012, 106 (9):1495-1498.
[7] Väisänen AH, Kallioinen M, Turpeenniemi-Hujanen T. Comparison of the prognostic value of matrix metalloproteinases 2 and 9 in cutaneous melanoma [J]. Hum Pathol, 2008, 39 (3): 377-385.
[8] Liu SC, Yang SF, Yeh KT, et al. Relationships between the level of matrix metalloproteinase-2 and tumor size of breast cancer [J]. Clin Chim Acta , 2006, 371(1/2): 92-96.
[9] Talvensaari-Mattila A, Pääkkö P, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma [J]. Br J Cancer, 2003, 89(7): 1270-1275.
[10]Kenny HA, Lengyel E. MMP-2 functions as an early response protein in ovarian cancer metastasis [J]. Cell Cycle, 2009, 8(5):683-688.
[11]Shapiro S, Khodalev O, Bitterman H, et al. Different activation forms of MMP-2 oppositely affect the fate of endothelial cells [J]. Am J Physiol Cell Physiol , 2010, 298(4):942-951.
[12]Zhou Y, Li G, Wu J, et al. Clinicopathological significance of E-cadherin, VEGF, and MMPs in gastric cancer [J]. Tumour Biol, 2010, 31 (6): 549-558.
[13]Xiang ZL, Zeng ZC, Fan J, et al. Expression profiling of fixed tissues identified hypoxia-inducible factor-1 alpha, VEGF, and matrix metalloproteinase-2 as biomarkers of lymph node metastasis in hepatocellular carcinoma [J]. Clin Cancer Res, 2011, 17(16): 5463-5472.
[14]Zhang Q, Chen X, Zhou J, et al. CD147, MMP-2, MMP-9 and MVD-CD34 are significant predictors of recurrence after liver transplantation in hepatocellular carcinoma patients [J]. Cancer Biol Ther, 2006, 5(7):808-814.
[15]Suhr F, Brixius K, Bloch W. Angiogenic and vascular modulation by extracellular matrix cleavage products [J]. Curr Pharm Des, 2009, 15(4):389-410.
[16]Hassona Y, Cirillo N, Heesom K, et al. Senescent cancer-associated fibroblasts secrete active MMP-2 that promotes keratinocyte dis-cohesion and invasion [J]. Br J Cancer, 2014, 111(6):1230-1237.
[17]Wang SY, Yu L, Ling GQ, et al. Vasculogenic mimicry and its clinical significance in medulloblastoma [J]. Cancer Biol Ther, 2012, 13(5):341-348.
[18]Guttman D, Stern Y, Shpitzer T, et al. Expression of MMP-9, TIMP-1, CD-34 and factor-8 as prognostic markers for squamous cell carcinoma of the tongue [J]. Oral Oncol, 2004, 40(8):798-803.
[19]Monteiro-Amado F, Castro-Silva II, Lima CJ, et al. Immunohistochemical evaluation of MMP-2, MMP-9 and CD31/microvascular density in squamous cell carcinomas of the floor of the mouth [J]. Braz Dent J, 2013, 24(1):3-9.